Trevena Preclinical Reveals TRV045 Data Providing Insight Into Novel Mechanism Of Analgesic Effect In Chronic Neuropathic Pain Model And Demonstrating Statistically Significant Anti-Seizure Activity In Epilepsy Models
Portfolio Pulse from Benzinga Newsdesk
Trevena's preclinical data on TRV045 reveals a novel mechanism for analgesic effects in chronic neuropathic pain and significant anti-seizure activity in epilepsy models.
June 20, 2024 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Trevena's preclinical data on TRV045 shows promising results for chronic neuropathic pain and epilepsy, which could boost investor confidence and stock price.
The positive preclinical results for TRV045 in treating chronic neuropathic pain and epilepsy could lead to increased investor confidence and a potential rise in Trevena's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100